FUCHS SE VZO NA O.N./ DE000A3E5D64 /
14/06/2024 13:36:59 | Diferencia -0.040 | Volumen | Bid13:40:20 | Ask13:43:18 | Capitalización de mecado | Dividendo A. | P/E Ratio |
---|---|---|---|---|---|---|---|
43.940EUR | -0.09% | 18,651 Volumen de negocios: 820,240.240 |
43.960Volumen de oferta: 110 | 44.040Tamaño/ Volumen/ Formato de Ask: 192 | 5.17 mil millonesEUR | 2.53% | 21.13 |
GlobeNewswire
14:00
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
GlobeNewswire
14:00
BIO-key Introduces Passkey:YOU, a Phish-resistant, Phoneless and Tokenless Biometric FIDO Passkey Au...
GlobeNewswire
14:00
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of ...
GlobeNewswire
14:00
Spectrum Group International Announces Extension of Election Deadline for Proposed Cash Election Mer...
GlobeNewswire
14:00
Summit Nanotech and Zelandez Collaborate to Accelerate Modular Lithium Carbonation Project in South ...
GlobeNewswire
14:00
LiveOne (Nasdaq: LVO) Announces 244th Edition of LiveOne Presents as Streaming Partner for “The Game...
GlobeNewswire
14:00
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritini...
GlobeNewswire
14:00
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored...
GlobeNewswire
13:50
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American...
GlobeNewswire
13:30
JOYY Inc. Announces the Results of the Repurchase Right Offer for its 1.375% Convertible Senior Note...
GlobeNewswire
13:30
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evalua...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página